<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02833584</url>
  </required_header>
  <id_info>
    <org_study_id>AMED2016</org_study_id>
    <nct_id>NCT02833584</nct_id>
  </id_info>
  <brief_title>Safety of Paracetamol as Antipyretic in Treatment of Dengue Infection in Adults</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phramongkutklao College of Medicine and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Phramongkutklao College of Medicine and Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether regular dosage of paracetamol causes
      transaminitis (hepatitis) and evaluate its potency in the treatment of dengue infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with abnormal serum transaminase levels on the last day of fever</measure>
    <time_frame>Day 1-8</time_frame>
    <description>Serum alanine transaminase and aspartate transaminase level will be measured at admission, and on every morning afterwards until the subject is discharged. The proportion of subjects with abnormal serum transaminase levels will be compared.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean serum transaminase level</measure>
    <time_frame>Day 1-8</time_frame>
    <description>Mean serum transaminase level will be compared.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change in serum transaminase levels</measure>
    <time_frame>Day 1-8</time_frame>
    <description>The change in serum transaminase levels from baseline at admission will be compared.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body temperature</measure>
    <time_frame>8 days</time_frame>
    <description>Axillary temperature will be recorded every 4 hours until discharge or 8 days after admission, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of fever</measure>
    <time_frame>8 days</time_frame>
    <description>Duration from the fever onset to the last febrile temperature will be compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>10 days</time_frame>
    <description>Duration from hospital admission to discharge will be compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of drug tablet used</measure>
    <time_frame>8 days</time_frame>
    <description>Number of drug tablet used will be compared, both paracetamol/placebo and tramadol.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Dengue</condition>
  <condition>Transaminitis</condition>
  <arm_group>
    <arm_group_label>Paracetamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will be randomised to receive Paracetamol prn for fever at maximum dosage of 500 mg PO q 4 hr (3 gm/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible patients will be randomised to receive Placebo prn for fever at maximum dosage of 500 mg PO q 4 hr (3 gm/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>Paracetamol 500 mg x 1 tablets according to patient's body weight</description>
    <arm_group_label>Paracetamol</arm_group_label>
    <other_name>Acetaminophen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 500 mg x 1 tablets according to patient's body weight</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient age &gt;18 years

          -  Dengue infection diagnosed by NS1 antigen, Dengue immunoglobulin M antibody, or
             polymerase chain reaction

          -  Admitted to the hospital

          -  Written informed consent from patient or attending relative able to and willing to
             give informed consent

        Exclusion Criteria:

          -  Other possible cause of fever other than dengue infection

          -  Pregnancy

          -  Unable to take medication

          -  Aminotransferase level above 3 times upper normal limit

          -  Allergy to paracetamol or tramadol

          -  Paracetamol indicated for condition other than dengue infection

          -  Critically ill patient who need ICU or invasive ventilation support

          -  History of cirrhosis

          -  Unable to comunicate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dhitiwat Changpradub, MD</last_name>
    <role>Study Director</role>
    <affiliation>Phramongkutklao College of Medicine and Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phramongkutklao College of Medicine and Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anandamahidol Hospital</name>
      <address>
        <city>Lopburi</city>
        <zip>15000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Adisorn Hospital</name>
      <address>
        <city>Saraburi</city>
        <zip>18000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2016</study_first_submitted>
  <study_first_submitted_qc>July 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>January 1, 2018</last_update_submitted>
  <last_update_submitted_qc>January 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Paracetamol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

